• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
  • Newsroom
    • Scientific Publications
    • Press Releases
    • Events
  • Partnering
  • Investors
    • Overview
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us

Press Releases

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

November 25, 2025 An Phan

Mont-Saint-Guibert, Belgium, November 25, 2025, 7pm CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency dated November 20, 2025, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has passively crossed above the 65% threshold, holding 49,050,641 voting rights, i.e. 67.77% of Celyad Oncology’s voting rights.

Content of the Notification:

  • Reason of the Notification:
  • Passive crossing of a threshold
  •  
  • Notification by:

A parent undertaking or a controlling person

  • Persons subject to the notification requirement:

Fortress Investment Group LLC – 1345 Avenue of the Americas, New York, NY 10105 United States

CFIP CLYD (UK) Limited – 7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom

  • Date on which the threshold is crossed:

November 14, 2025

  • Threshold that is crossed (in %):

65

  • Denominator:

72,383,166

  • Notified details:
A) Voting RightsPrevious notificationAfter the Transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to the securitiesNot linked to the securitiesLinked to the securitiesNot linked to the securities
Fortress Investment Group LLC0000.00 %0.00 %
CFIP CLYD (UK) Limited34,146,79549,050,641067.77%0.00 %
Subtotal34,146,79549,050,641 67.77% 
 TOTAL49,050,641067.77%0.00 %
B) Equivalent financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
     
TOTAL 00.00% 
TOTAL (A & B) # of voting rights% of voting rights
CALCULATE49,050,64167.77%
  • Full chain of controlled undertakings through which the holdings is effectively held:
    • CFIP CLYD (UK) Limited (“CFIP UK”), a UK limited liability company directly holds 49,050,641 voting rights in the issuer.
    • CFIP CLYD LLC, a Delaware limited liability company (“CFIP”), is the parent of CFIP UK.
    • FIP II UB Investments LP, a Delaware limited partnership (“FIP II”), holds 50% of the membership interests in CFIP.
    • FIP Fund II GP LLC, a Delaware limited liability company (“FIP II GP”), is the general partner of FIP II.
    • Hybrid GP Holdings LLC, a Delaware limited liability company (“Hybrid GP”), is the parent of FIP II GP and indirectly controls the general partners of certain investment funds that hold membership interests in CFIP.
    • FIG LLC, a Delaware limited liability company (“FIG LLC”), is an investment advisor registered with the US Securities and Exchange Commission and indirectly controls the investment advisers to certain investment funds that hold membership interests in CFIP.
    • Fortress Operating Entity I LP, a Delaware limited partnership (“FOE I”), is (i) the sole owner of FIG LLC and (ii) the managing member of, and holds the majority of equity interest in, Hybrid GP.
    • FIG Blue LLC (formerly known as FIG Corp.), a Delaware limited liability company (“FIG Blue”) is the general partner of FOE I.
    • Fortress Investment Group LLC, a Delaware limited liability company (“Fortress”) is the sole owner of FIG Blue. Fortress, acting through the investment advisers owned and controlled by FIG LLC, holds discretionary authority over the funds that indirectly hold the membership interests in CFIP, and can exercise the voting rights associated therewith without any instruction from its clients. Fortress is not a controlled entity.
  • Additional information:

This transparency notification relates to the passive upward crossing of the 65% threshold. This results from the fact that the shares that were issued by Celyad on 14 November 2023 in the context of a private placement (the 2023 Private Placement) bear double voting rights as from 14 November 2025. CFIP CLYD (UK) Limited had on 14 November 2023 subscribed to 14,903,846 new shares in Celyad and these shares now bear double voting rights, bringing the total number of shares with double voting right in Celyad held by CFIP CLYD (UK) Limited to 22,858,654 and the total number of voting rights held by CFIP CLYD (UK) Limited to 49,050,641.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Press Releases, regulated information

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

November 14, 2025 An Phan

Mont-Saint-Guibert, Belgium, November 14, 2025, 7:00 pm CET – regulated information – Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that 14,903,846 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of November 14, 2025. As a result, the Company’s total number of voting rights is now 72,383,166.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions

 Figures – Modified on November 14, 2025, following the Double Voting Rights:

Total amount of share capital (EUR)9,216,154.53
Total Number of shares with single voting rights17,140,644
Total Number of shares with double voting rights27,621,261
Total Number of Shares44,761,905
Total of voting rights72,383,166
Total number of attributed warrants3,856,134
Total number of shares with voting rights that could be created following the exercise of the attributed warrants3,856,134
Total number of diluted shares (Outstanding shares + Warrants)48,618,039
Total number of diluted shares with voting rights76,239,300

Contact person for regulated information (financial, transparency)

By law, any transparency declaration must be sent to our Company by email to the attention of Matthew Kane, Chief Executive Officer (CEO): investors@celyad.com  

Further questions about the content of this release can be sent to investors@celyad.com

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Press Releases, regulated information

Celyad Oncology Announces Research Facility Divestiture

September 29, 2025 Caroline Lonez

Mont-Saint-Guibert, Belgium; September 29, 2025, 6:30 pm CET; regulated information / inside information – Celyad Oncology (Euronext: CYAD) (the “Company”), today announces the divestment of the Company’s research facility.

Under the terms of an asset purchase agreement, the Company shall sell its research facility’s equipment and office furniture in Mont-Saint-Guibert, Belgium, for a total consideration of €3 million. The transaction is subject to a number of customary conditions precedent and is anticipated to close in the fourth quarter of this year. Management currently anticipates that this transaction will extend the cash runway of the Company by approximatively three quarters, i.e. into Q3-2026.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: inside information, Press Releases, regulated information

Celyad Oncology reports first half year 2025 financial results

September 25, 2025 Caroline Lonez

Mont-Saint-Guibert, Belgium; September 25, 2025, 6:30 pm CET; regulated information – Celyad Oncology (Euronext: CYAD) (the “Company”), today announced its financial results for the first half year 2025 ended June 30, 2025.

First Half  2025 financial review

As of June 30, 2025, the Company’s Treasury position amounted to €0.8 million.

After due consideration of detailed budgets and estimated cash flow forecasts for the years 2025 and 2026, the Company projects that its existing cash and cash equivalents will be sufficient to fund its estimated operating and capital expenditures into the fourth quarter of 2025.

Key financial figures for first half 2025, compared with the first half of 2024 and full year 2024, are summarized below:

Selected key financial figures (€ millions)Half Year 30 June 2025Half Year 30 June 2024Full Year 31 December 2024
Revenue––0.2
Research and development expenses(2.1)(1.5)(3.2)
General and administrative expenses(1.7)(1.7)(3.2)
Other income/(expenses)0.10.20.4
Operating loss(3.7)(3.1)(5.9)
Loss for the period/year(3.7)(3.0)(5.9)
Net cash used in operations(3.3)(2.8)(5.7)
Cash and cash equivalents0.86.24.2


Research and Development (R&D) expenses were €2.1 million in June 2025 as compared to €1.5 million during the same period in 2024, an increase of €0.6 million. The increase in the Company’s R&D expenses was primarily driven by the increase of the IP costs related to the licensing activities as well as the increase of the expenses linked to the redevelopment of the catheter.

General and Administrative (G&A) expenses remained stable with €1.7 million in June 2025 as in June 2024.

Net loss for the first half of 2025, was €3.7 million, or €(0.09) per share, compared to a net loss of €3.0 million, or €(0.07) per share, for the same period in 2024.

Net cash used in operations was €3.3 million for the first half of 2025 compared to €2.8 million for the first half of 2024. The increase of €0.5 million was primarily driven by the global increase of IP activities and catheter development costs.

As of June 30, 2025, the Company had cash and cash equivalents of €0.8 million. No capital increase occurred in the first half of 2025. The total number of basic shares outstanding was 41.4 million like in December 31, 2024.

The interim financial report for first half 2025 of the Company can be found on our website:  https://celyad.com/investors/

Financial Calendar 2025

May 20th 2026 : Annual shareholders meeting               
September 24th 2026 : First Half 2026 Interim results

The financial calendar is communicated on an indicative basis and may be subject to change.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Financial Reports, Press Releases, regulated information

Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)

September 11, 2025 Caroline Lonez

Mont-Saint-Guibert, Belgium, September 11, 2025, 06:30 pm CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency dated September 08, 2025, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, has passively crossed below the 60% threshold, holding 34,146,795 voting rights, i.e. 59.41% of Celyad Oncology’s voting rights.

Content of the Notification:

  • Reason of the Notification:

Passive crossing of a threshold

  • Notification by:

A parent undertaking or a controlling person

  • Persons subject to the notification requirement:

Fortress Investment Group LLC – 1345 Avenue of the Americas, New York, NY 10105 United States

CFIP CLYD (UK) Limited – 7 Clarges Street, 4th Floor, London W1J 8AE, United Kingdom

  • Date on which the threshold is crossed:

September 04, 2025

  • Threshold that is crossed (in %):

60

  • Denominator:

57,479,320

  • Notified details:
A) Voting RightsPrevious notificationAfter the Transaction
 # of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to the securitiesNot linked to the securitiesLinked to the securitiesNot linked to the securities
Fortress Investment Group LLC0000.00 %0.00 %
CFIP CLYD (UK) Limited32,691,98734,146,795059.41%0.00 %
Subtotal32,691,98734,146,795 59.41% 
 TOTAL34,146,795059.41%0.00 %
B) Equivalent financial instrumentsAfter the transaction
Holders of equivalent financial instrumentsType of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
     
TOTAL 00.00% 
TOTAL (A & B) # of voting rights% of voting rights
CALCULATE34,146,79559.41%
  • Full chain of controlled undertakings through which the holdings is effectively held:
    • CFIP CLYD (UK) Limited (“CFIP UK”), a UK limited liability company directly holds 34,146,795 voting rights in the issuer. 
    • CFIP CLYD LLC, a Delaware limited liability company (“CFIP”), is the parent of CFIP UK.
    • FIP II UB Investments LP, a Delaware limited partnership (“FIP II”), holds 50% of the membership interests in CFIP.
    • FIP Fund II GP LLC, a Delaware limited liability company (“FIP II GP”), is the general partner of FIP II.
    • Hybrid GP Holdings LLC, a Delaware limited liability company (“Hybrid GP”), is the parent of FIP II GP and indirectly controls the general partners of certain investment funds that hold membership interests in CFIP. 
    • FIG LLC, a Delaware limited liability company (“FIG LLC”), is an investment advisor registered with the US Securities and Exchange Commission and indirectly controls the investment advisers to certain investment funds that hold membership interests in CFIP.
    • Fortress Operating Entity I LP, a Delaware limited partnership (“FOE I”), is (i) the sole owner of FIG LLC and (ii) the managing member of, and holds the majority of equity interest in, Hybrid GP.
    • FIG Blue LLC (formerly known as FIG Corp.), a Delaware limited liability company (“FIG Blue”) is the general partner of FOE I.
    • Fortress Investment Group LLC, a Delaware limited liability company (“Fortress”) is the sole owner of FIG Blue. Fortress, acting through the investment advisers owned and controlled by FIG LLC, holds discretionary authority over the funds that indirectly hold the membership interests in CFIP, and can exercise the voting rights associated therewith without any instruction from its clients.
  • Additional information:

This transparency notification relates to the passive downward crossing of the 60% threshold. This results from the fact that the shares that were issued by Celyad Oncology on 4 September 2023 in the context of a private placement (the “2023 Private Placement”) bear double voting rights as from 4 September 2025.

CFIP CLYD (UK) Limited had on 4 September 2023 subscribed to 1,454,808 new shares in Celyad Oncology and these shares now bear double voting rights, bringing the total number of shares with double voting right in Celyad Oncology held by CFIP CLYD (UK) Limited to 7,954,808 and the total number of voting rights held by CFIP CLYD (UK) Limited to 34,146,795. As another shareholder of Celyad Oncology had subscribed to a larger stake in the 2023 Private Placement and because all such shares equally bear double voting rights as from 4 September 2025, CFIP CLYD (UK) Limited’s overall percentage of voting rights in Celyad Oncology has decreased to 59.41%.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Press Releases, regulated information, Transparency Declaration Tagged With: Transparency

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

September 4, 2025 Caroline Lonez

Mont-Saint-Guibert, Belgium, September 4, 2025, 07:00 am CET – regulated information – Celyad Oncology (Euronext: CYAD) (“Celyad” or the “Company”), today announced that 3,849,040 registered shares benefit from a double voting right as of September 4, 2025. As a result, the Company’s total number of voting rights is now 61,335,454.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

 Figures – Modified on September 4, 2025, following the Double Voting Rights:

Total amount of share capital (EUR)9,216,154.53
Total Number of shares with single voting rights32,044,490
Total Number of shares with double voting rights12,717,415
Total Number of Shares44,761,905
Total of voting rights57,479,320
Total number of attributed warrants3,856,134
Total number of shares with voting rights that could be created following the exercise of the attributed warrants3,856,134
Total number of diluted shares (Outstanding shares + Warrants)48,618,039
Total number of diluted shares with voting rights61,335,454

Contact person for regulated information (financial, transparency)

By law, any transparency declaration must be sent to our Company by email to the attention of Matthew Kane, Chief Executive Officer (CEO): investors@celyad.com  

Further questions about the content of this release can be sent to investors@celyad.com

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Press Releases, regulated information

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Interim pages omitted …
  • Page 21
  • Go to Next Page »

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Newsroom
  • Partnering
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2026 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use